{"id":235,"date":"2015-01-30T04:20:52","date_gmt":"2015-01-30T04:20:52","guid":{"rendered":"http:\/\/beasleypharmabio.com\/?page_id=235"},"modified":"2019-07-20T17:00:26","modified_gmt":"2019-07-20T21:00:26","slug":"vitae","status":"publish","type":"page","link":"https:\/\/beasleypharmabio.com\/?page_id=235","title":{"rendered":"Curriculum Vitae"},"content":{"rendered":"
\n\t
\n\t\t
\n\t\t
\n\t\t\t

UNDERGRADUATE EDUCATION<\/h3>\n

Yale University<\/h4>\n

B.A., 1977, Psychology<\/p>\n

University of Kentucky<\/h4>\n

Additional courses, Computer Science<\/p>\n\n\t\t<\/div> \n\t<\/div>

<\/div>\n
\n\t\t
\n\t\t\t

MEDICAL EDUCATION<\/h3>\n

University of Kentucky<\/h4>\n

College of Medicine, M.D., 1983<\/p>\n\n\t\t<\/div> \n\t<\/div>

<\/div>\n
\n\t\t
\n\t\t\t

POSTGRADUATE TRAINING<\/h3>\n

Yale University<\/h4>\n

Department of Psychiatry;\u00a0PGY-I, 1983-84
\nFlexible intern at the Hospital of St. Raphael<\/p>\n

University of Cincinnati<\/h4>\n

Department of Psychiatry;\u00a0PGY-II-IV, 1984-87
\nGeneral Psychiatry residency<\/p>\n\n\t\t<\/div> \n\t<\/div>

<\/div>\n
\n\t\t
\n\t\t\t

CERTIFICATION AND LICENSURE<\/h3>\n

National Board of Medical Examiners<\/h4>\n

Diplomate, 1984<\/p>\n

American Board of Psychiatry and Neurology<\/h4>\n

Diplomate (Psychiatry), 1988<\/p>\n

State of Ohio; State of Indiana<\/h4>\n

Medical License<\/p>\n\n\t\t<\/div> \n\t<\/div> \n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t

AWARDS AND HONORS<\/h3>\n

Sandoz Pharmacology Award<\/h4>\n

2nd\u00a0year medical school<\/p>\n

Promoted with distinction<\/h4>\n

2nd\u00a0and 3rd\u00a0years medical school<\/p>\n

Elected to AOA and AOA president<\/h4>\n

3rd\u00a0year medical school<\/p>\n

AMA-ERF Rock Sleyster Memorial Scholar<\/h4>\n

4th year medical school<\/p>\n

Cornelia B. Wilbur Psychiatry Departmental Award<\/h4>\n

4th\u00a0year medical school<\/p>\n

Neurology Departmental Award<\/h4>\n

4th\u00a0year medical school<\/p>\n

Graduated medical school with high distinction<\/h4>\n

1983<\/p>\n

Laughlin Fellow<\/h4>\n

American College of Psychiatrists, 1987<\/p>\n

1st\u00a0place, Maurice Levine Essay Award<\/h4>\n

Cincinnati Psychiatric Society, 1987<\/p>\n

4th\u00a0Year Resident\u2019s Award<\/h4>\n

Department of Psychiatry, University of Cincinnati, 1987<\/p>\n

Resident\u2019s Research Award<\/h4>\n

Department of Psychiatry, University of Cincinnati, 1987<\/p>\n

Founder\u2019s Day Resident Award Paper<\/h4>\n

Ohio Psychiatric Association, 1987<\/p>\n\n\t\t<\/div> \n\t<\/div> \n\t<\/div> \n<\/div>

\n\t
\n\t\t
<\/div>\n
\n\t\t
\n\t\t\t

Professional Activities<\/h2>\n\n\t\t<\/div> \n\t<\/div>
<\/div>\n\n\t<\/div> \n<\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t

PROFESSIONAL POSITIONS<\/h3>\n

10\/04 to Present<\/em><\/p>\n

Distinguished Lilly Scholar, Global Patient Safety<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

4\/04 to 10\/04<\/em><\/p>\n

Distinguished Lilly Medical Fellow and Chief Scientific Officer for Global Patient Safety<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

1\/03 to 4\/04<\/em><\/p>\n

Lilly Clinical Research Fellow and Consultant in Neurosciences<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

7\/01 to 1\/03<\/em><\/p>\n

Lilly Clinical Research Fellow and Medical Director Cialis Product Team<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

7\/99 to 7\/01<\/em><\/p>\n

Lilly Clinical Research Fellow and Consultant in Neurosciences<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

1\/96 to 7\/99<\/em><\/p>\n

Medical Advisor, Olanzapine Development Team<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

1\/95 to 1\/96<\/em><\/p>\n

Senior Research Physician, Olanzapine Development Team<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

3\/92 to 1\/95<\/em><\/p>\n

Senior Research Physician, Division of Psychopharmacology, Clinical Investigation and Regulatory Affairs<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

8\/91 to 3\/92<\/em><\/p>\n

Research Physician, Division of Psychopharmacology, Clinical Investigation and Regulatory Affairs<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

8\/90 to 8\/91<\/em><\/p>\n

Research Physician, Division of Fluoxetine Clinical Investigation, Clinical Investigation and Regulatory Affairs<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

7\/89 to 8\/90<\/em><\/p>\n

Research Physician, Division of Clinical Neurosciences, Clinical Investigation and Regulatory Affairs<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

7\/87 to 7\/89<\/em><\/p>\n

Associate Research Physician, Division of Clinical Neurosciences, Clinical Investigation and Regulatory Affairs<\/h4>\n

Lilly Research Laboratories, Eli Lilly and Company<\/p>\n

5\/87 to 6\/87<\/em><\/p>\n

Physician<\/h4>\n

Group Health Associates, Cincinnati, Ohio<\/p>\n

7\/85 to 3\/87<\/em><\/p>\n

Consultant, Eating Disorders Center<\/h4>\n

Department of Psychiatry, University of Cincinnati Medical Center<\/p>\n

6\/85 to 5\/86<\/em><\/p>\n

Physician, Affective Disorders Center<\/h4>\n

Department of Psychiatry, University of Cincinnati Medical Center<\/p>\n

7\/78 to 8\/79<\/em><\/p>\n

Associate in Research, Neuropsychology Laboratory<\/h4>\n

Department of Neurology, Yale University School of Medicine and West Haven Veterans Administration Hospital<\/p>\n

6\/77 to 7\/78<\/em><\/p>\n

Research Programmer<\/h4>\n

Department of Psychology, Yale University<\/p>\n\n\t\t<\/div> \n\t<\/div>

<\/div>\n
\n\t\t
\n\t\t\t

ACADEMIC APPOINTMENTS<\/h3>\n

1\/89 to 6\/96<\/em><\/p>\n

Voluntary Assistant Professor<\/h4>\n

Department of Psychiatry, University of Cincinnati<\/p>\n\n\t\t<\/div> \n\t<\/div> \n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t

PROFESSIONAL SOCIETY\u00a0FELLOWSHIPS<\/h3>\n

Distinguished Life Fellow, American Psychiatric Association
\nFellow, American College of Psychiatrists
\nFellow, American College of Neuropsychopharmacology
\nFellow, American Society of Clinical Psychopharmacology\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fellow, Royal College of Physicians of the United Kingdom Faculty of Pharmaceutical Medicine<\/p>\n\n\t\t<\/div> \n\t<\/div>

<\/div>\n
\n\t\t
\n\t\t\t

PROFESSIONAL SOCIETY MEMBERSHIPS<\/h3>\n

Indiana Psychiatric Society<\/p>\n\n\t\t<\/div> \n\t<\/div>

<\/div>\n
\n\t\t
\n\t\t\t

EDITORIAL BOARD MEMBERSHIPS<\/h3>\n

Co-Editor, Psychopharmacology<\/strong>
\nThe Open Pharmacology Journal<\/em><\/p>\n\n\t\t<\/div> \n\t<\/div>

<\/div>\n
\n\t\t
\n\t\t\t

REVIEWER<\/h3>\n

Journal of Clinical Psychopharmacology<\/em>
\n Archives of General Psychiatry<\/em>
\n Psychological Bulletin<\/em>
\n Psychological Medicine<\/em>
\n Biological Psychiatry<\/em>
\n Neuropsychiatric Diseases and Treatment<\/em>
\n Progress in Nero-Psychopharmacology & Biological Psychiatry<\/em>
\n American Journal of Psychiatry<\/em><\/p>\n\n\t\t<\/div> \n\t<\/div>

<\/div>\n
\n\t\t
\n\t\t\t

OTHER PROFESSIONAL ACTIVITIES<\/h3>\n\n\t\t<\/div> \n\t<\/div>
\n\t\t
\n\t\t\t

Reviewer<\/strong>
\nHanson S, Davis M, Altevogt B.\u00a0 CNS Clinical Trials: Suicidality and Data Collection Workshop Summary.<\/em>\u00a0 Washington, DC:\u00a0 Institute of Medicine, 2010.<\/p>\n

History Committee<\/strong>
\nAmerican College of Neuropsychopharmacology
\n2008-2010<\/p>\n\n\t\t<\/div> \n\t<\/div>

\n\t\t
\n\t\t\t

Co-chairperson<\/strong>
\nPMA Education & Research Institute
\nPharmacology Training Series:
\nCentral Nervous System Pharmacology
\nWashington, D.C.
\nSep 29-30, 1993<\/p>\n\n\t\t<\/div> \n\t<\/div>

\n\t\t
\n\t\t\t

Co-chairperson<\/strong>
\nPaper Session 41:\u00a0Comorbidity in affective disorders
\nAmerican Psychiatric Association Annual Meeting
\nMontreal, Canada
\nMay 12, 1988<\/p>\n\n\t\t<\/div> \n\t<\/div> \n\t<\/div> \n<\/div>

\n\t
\n\t\t
<\/div>\n
\n\t\t
\n\t\t\t

INVITED REPRESENTATIONS (selected)<\/h3>\n
    \n
  1. Beasley C<\/span>
    \nA tale of two profiles: the hemodynamic effects of atomoxetine under clinical observation vs. intensive monitoring<\/strong>
    \nCardiac Safety Research Consortium \u2013 Pediatric Cardiovascular Safey Drug and Medical Device Development Thinktank. Silver Spring, MD, Dec. 10, 2010.<\/li>\n
  2. Beasley C<\/span>
    \nAre there ways to create robust and informative datasets through pooling?<\/strong>
    \nWorkshop on CNS Clinical Trials: suicidality and data collection\u00a0 Sponsored by the Institute of Medicine.\u00a0 Washington, DC, June 16, 2009.<\/li>\n
  3. Beasley C<\/span>
    \nHow to characterize the QT effect in the targeted patient population when a TQT study is positive<\/strong>
    \nDIA Conference: Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding. Arlington, VA, Apr. 12, 2009.<\/li>\n
  4. Beasley C<\/span>
    \nAssessment of fluoxetine and suicide<\/strong>
    \nThinktank on Assessment of Treatment-Emergent Suicidality sponsored by Best Practices Project Management, Inc. and Department of Psychiatry, Harvard Medical School.\u00a0 Washington, DC, Mar 23-24, 2009.<\/li>\n
  5. Beasley C<\/span>
    \nRegulatory, procedural, and statistical considerations in the thorough QT study: the complexity of the design of a thorough QT study<\/strong>
    \nWorld Pharmaceutical Congress. Philadelphia, PA,\u00a0May 12, 2008.<\/li>\n
  6. Beasley C<\/span>
    \nConduct & Design of a TQT Study<\/strong>
    \nKeynote address. QT and Drug Development. London, England, Oct. 24, 2007.<\/li>\n
  7. Beasley C<\/span>
    \nEffective strategies for designing thorough QT studies<\/strong>
    \neXlpharma webinar. Sept. 27, 2007.<\/li>\n
  8. Beasley C<\/span>
    \nWhy we need improved preclinical predictors and human biomarkers for torsades de pointe<\/strong>
    \nKeynote presentation, Cardiac Safety.\u00a0World Pharmaceutical Congress. Philadelphia, PA, June 12, 2007.<\/li>\n
  9. Beasley C<\/span>
    \nIs 36,000 ECGs overkill?<\/strong>
    \nDIA Conference \u2013 Challenges and Practical Aspects of Assessing Clinical QT Prolongation \/ Proarrhythmia Risk and Implications for the Critical Pathway. Washington, DC, May 9, 2006.<\/li>\n
  10. Beasley C<\/span>
    \nDo we need a new ear, a new purse, or both? OR What do we need to more effectively and efficiently confirm the absence of risk of torsades?<\/strong>
    \nCardiac Safety and Critical Pathway Initiative Regulatory Think-Tank. Bethesda, MD, Oct. 11, 2005.<\/li>\n
  11. Beasley C<\/span>
    \nFluoxetine and suicidality revisited<\/strong>
    \nA Workshop on Antidepressants and suicide.\u00a0 Sponsored by Department of Psychiatry, Columbia College of Physicians and Surgeons and New York State Psychiatric Institute.\u00a0 New York, NY. Apr. 19, 2005.<\/li>\n
  12. Beasley C<\/span>
    \nDrug development from the industry perspective: challenges and opportunities<\/strong>
    \nA Workshop on Clinical Trials in Psychopharmacology. New York, NY, Apr. 12, 2005.<\/li>\n
  13. Beasley C<\/span>
    \nOlanzapine<\/strong>
    \nBritish Association for Psychopharmacology Regional Meeting. Guilford, England, Oct. 10, 1997.<\/li>\n
  14. Beasley C<\/span>
    \nOlanzapine: atypical antipsychotic<\/strong>
    \nAmerican Society of Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, Mar. 21, 1996.<\/li>\n
  15. Beasley C<\/span>
    \nOlanzapine clinical development: molecule to drug candidate<\/strong>
    \nNCDEU Annual Meeting. Orlando, FL, June 1, 1995.<\/li>\n
  16. Beasley C<\/span>
    \nClinical trial design in depression and anxiety<\/strong>
    \nPMA Education and Research Institute Course Drug Development in Depression and Anxiety. Boston, MA, Mar. 15, 1994.<\/li>\n
  17. Beasley C<\/span>
    \nAtypical antipsychotics: What are they?<\/strong>
    \nGrand Rounds, Cleveland Clinic. Cleveland, OH, Nov. 4, 1993.<\/li>\n
  18. Beasley C<\/span>
    \nOlanzapine<\/strong>
    \nInternational Congress on Schizophrenia Research. Colorado Springs, CO, Apr. 20, 1993.<\/li>\n
  19. Beasley C<\/span>
    \nFluoxetine in tricyclic refractory major depressive disorder<\/strong>
    \nSecond International Conference on Refractory Depression. Amsterdam, The Netherlands, June 26, 1992.<\/li>\n
  20. Beasley C<\/span>
    \nFluoxetine: significance of plasma concentrations and impact on psychomotor performance<\/strong>
    \n1992 Annual Lectureship in Forensic Toxicology. Annual meeting of the American Academy of Forensic Sciences. New Orleans, LA, Feb. 21, 1992.<\/li>\n
  21. Beasley C, Farries D<\/span>
    \nFluoxetine: worldwide suicidality data<\/strong>
    \nAnnual Meeting of the American College of Neuropsychopharmacology \u00a0(Study Group). San Juan, PR, Dec. 11, 1991.<\/li>\n
  22. Beasley C, Farries D<\/span>
    \nStrategies to lower placebo response rates in depressed patients in antidepressant trials<\/strong>
    \nAnnual Meeting of the American College of Neuropsychopharmacology (Study Group). San Juan, PR, Dec. 9, 1991.<\/li>\n
  23. Beasley C, Dornseif B<\/span>
    \nPlacebo response in depression: associated variables?<\/strong>
    \nAnnual Meeting of the American College of Neuropsychopharmacology(Study Group).\u00a0Maui,\u00a0HA, Dec. 13, 1989.<\/li>\n
  24. Beasley C<\/span>
    \nTSH response to TRH and differential drug response in psychosis<\/strong>
    \nFounder\u2019s Day Resident Award Paper Presentation, Ohio Psychiatric Association. Toledo, OH, Apr. 23, 1988.<\/li>\n
  25. Beasley C<\/span>
    \nMedication response subtyping of psychoses and neuroendocrine correlates<\/strong>
    \nIndiana University Psychiatric Research Institute Seminar. Indianapolis, IN, Nov. 5, 1987.<\/li>\n
  26. Beasley C<\/span>
    \nSerotonin uptake inhibitors in psychiatry<\/strong>
    \nAnnual Convention of the Central Neuropsychiatric Association. Indianapolis, IN, Oct. 10, 1987.<\/li>\n
  27. Beasley C<\/span>
    \nTSH response to TRH and medication response subtypes of psychoses<\/strong>
    \nMaurice Levine Essay Award Presentation, Cincinnati Psychiatric Society. Cincinnati, OH, Apr. 15, 1987.<\/li>\n
  28. Garver D, Beasley C<\/span>
    \nHeterogeneity of neuroleptic response in psychosis: implications for subtyping<\/strong>
    \nPsychiatric Research Society Annual Meeting. Tampa, FL, Apr. 4, 1987.<\/li>\n
  29. Beasley C, Garver D<\/span>
    \nThe heterogeneity of schizophrenic illness(es)<\/strong>
    \nAnnual Meeting & Scientific Symposium, Mental Health Association in Ohio. Columbus, OH, Oct. 10, 1986.<\/li>\n
  30. Beasley C<\/span>
    \nThe acquisition of procedural knowledge: some linguistic examples<\/strong>
    \nUniversity of Kentucky Linguistics Circle. Lexington, KY, Apr. 9, 1980.<\/li>\n<\/ol>\n\n\t\t<\/div> \n\t<\/div> \n\t<\/div> \n<\/div>\n","protected":false},"excerpt":{"rendered":"UNDERGRADUATE EDUCATION Yale University B.A., 1977, Psychology University of Kentucky Additional courses, Computer Science MEDICAL EDUCATION University of Kentucky College of Medicine, M.D., 1983 POSTGRADUATE TRAINING Yale University Department of Psychiatry;\u00a0PGY-I, 1983-84 Flexible intern at the Hospital of St. Raphael University of Cincinnati Department of Psychiatry;\u00a0PGY-II-IV, 1984-87 General Psychiatry residency CERTIFICATION AND LICENSURE National Board [...]","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/pages\/235"}],"collection":[{"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=235"}],"version-history":[{"count":12,"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/pages\/235\/revisions"}],"predecessor-version":[{"id":400,"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=\/wp\/v2\/pages\/235\/revisions\/400"}],"wp:attachment":[{"href":"https:\/\/beasleypharmabio.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}